← All trials
NCT04044131
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2019
- Primary completion
- Sep 30, 2020
- Completion date
- Sep 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Istanbul Medipol UniversityLead sponsor
- University of GothenburgCollaborator
- Istanbul Medipol UniversityReponsible party - principal investigator
- Istanbul Medipol UniversityOverall official - principal investigator
- ScandiBio Therapeutics ABCollaborator
- KTH Royal Institute of TechnologyCollaborator
- Alanya Alaaddin Keykubat UniversityCollaborator
- Alanya Alaaddin Keykubat UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.